Published in Rheumatology (Oxford) on January 19, 2008
Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. Arthritis Rheum (2009) 1.54
Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis. Expert Rev Vaccines (2015) 0.79
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature (1985) 9.62
Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell (1997) 8.72
Requirement for Xist in X chromosome inactivation. Nature (1996) 8.24
The product of the mouse Xist gene is a 15 kb inactive X-specific transcript containing no conserved ORF and located in the nucleus. Cell (1992) 6.26
Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet (2000) 4.74
Conservation of position and exclusive expression of mouse Xist from the inactive X chromosome. Nature (1991) 3.43
A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell (1999) 3.36
A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs. Am J Hum Genet (1999) 2.15
Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer (2005) 2.13
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol (1994) 2.02
Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J Cell Sci (1996) 1.99
A Taq I polymorphism for the human transforming growth factor alpha gene (TGFA). Nucleic Acids Res (1987) 1.88
Evidence that random and imprinted Xist expression is controlled by preemptive methylation. Cell (1994) 1.88
Genome scan of schizophrenia. Am J Psychiatry (1998) 1.74
Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res (2000) 1.72
MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet (2001) 1.67
Leptin and the risk of Barrett's oesophagus. Gut (2008) 1.54
DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. Oncogene (2009) 1.53
The CDKN2A (p16) gene and human cancer. Mol Med (1997) 1.46
Gene expression of lung squamous cell carcinoma reflects mode of lymph node involvement. Eur Respir J (2007) 1.43
Murine cerberus homologue mCer-1: a candidate anterior patterning molecule. Dev Biol (1998) 1.41
Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol (1996) 1.36
Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res (1997) 1.33
The contribution of the DFNB1 locus to neurosensory deafness in a Caucasian population. Am J Hum Genet (1995) 1.30
Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer (1996) 1.25
Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res (1994) 1.24
Bisulfite genomic sequencing-derived methylation profile of the xist gene throughout early mouse development. Genomics (1998) 1.24
Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet (1995) 1.18
Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas. Melanoma Res (1995) 1.10
Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res (1996) 1.10
Suckling defect in mice lacking the soluble haemopoietin receptor NR6. Curr Biol (1999) 1.09
Autocrine mitogen IgEGF cooperates with c-myc or with the Hcs locus during hepatocarcinogenesis in transgenic mice. Oncogene (1995) 1.08
Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene. Br J Cancer (2000) 1.07
CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res (1997) 1.07
X-linked aqueductal stenosis: clinical and neuropathological findings in two families. Pediatrics (1973) 1.06
Separate and interacting effects within the catechol-O-methyltransferase (COMT) are associated with schizophrenia. Mol Psychiatry (2005) 1.04
Re-excision operations in nonpalpable breast cancer. J Surg Oncol (1995) 1.04
Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst (2010) 1.04
Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res (2001) 1.03
Methylation analysis using bisulfite genomic sequencing: application to small numbers of intact cells. Biotechniques (1997) 1.02
Analysis of gene amplification in head-and-neck squamous-cell carcinoma. Int J Cancer (1991) 1.00
Bex1, a gene with increased expression in parthenogenetic embryos, is a member of a novel gene family on the mouse X chromosome. Hum Mol Genet (1999) 0.98
Second stage of a genome scan of schizophrenia: study of five positive regions in an expanded sample. Am J Med Genet (2000) 0.98
Germline CDKN2A mutations in childhood melanoma. J Natl Cancer Inst (1997) 0.98
Localization of multiple melanoma tumor-suppressor genes on chromosome 11 by use of homozygosity mapping-of-deletions analysis. Am J Hum Genet (2000) 0.97
Functional reassessment of P16 variants using a transfection-based assay. Int J Cancer (1999) 0.97
Effects of prenatal dexamethasone on spatial learning and response to stress is influenced by maternal factors. Am J Physiol Regul Integr Comp Physiol (2000) 0.96
Hepatocellular carcinoma mutation. Nature (1991) 0.95
Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene (1997) 0.94
A genetic model of melanoma tumorigenesis based on allelic losses. Genes Chromosomes Cancer (1995) 0.93
Teaching palliative care in general practice: a survey of educational needs and preferences. J Palliat Care (1991) 0.91
Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat (1998) 0.90
DAN is a secreted glycoprotein related to Xenopus cerberus. Mech Dev (1998) 0.90
Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome arm 1p in 7 Australian pedigrees. Genomics (1992) 0.90
The nature of conditioning nutrients for human malignant melanoma cultures. J Cell Sci (1983) 0.89
Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene (1995) 0.89
Ferricyanide can replace pyruvate to stimulate growth and attachment of serum restricted human melanoma cells. Biochem Biophys Res Commun (1983) 0.89
The phospholipase C beta 3 gene located in the MEN1 region shows loss of expression in endocrine tumours. Hum Mol Genet (1994) 0.88
Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res (2002) 0.88
PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Res (2002) 0.87
p53 gene in hepatocellular carcinomas from Australia. Cancer Detect Prev (1994) 0.86
Clonal loss of INT-2 alleles in sporadic and familial pancreatic endocrine tumours. Br J Cancer (1990) 0.86
Simple tandem repeat allelic deletions confirm the preferential loss of distal chromosome 6q in melanoma. Int J Cancer (1994) 0.86
Multiple splicing variants of cdc25B regulate G2/M progression. Biochem Biophys Res Commun (1999) 0.86
CDKN2A is not the principal target of deletions on the short arm of chromosome 9 in neuroendocrine (Merkel cell) carcinoma of the skin. Int J Cancer (2001) 0.86
Loss of somatic heterozygosity in hepatocellular carcinoma. Cancer Res (1991) 0.86
Interaction between Six-month-old peers. Child Dev (1983) 0.85
Evidence for microsatellite instability in bilateral breast carcinomas. Cancer Lett (2000) 0.85
CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. Int J Cancer (1997) 0.85
Linkage mapping of melanoma (MLM) using 172 microsatellite markers. Genomics (1992) 0.85
Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer. Anticancer Drugs (1996) 0.85
Responses of six-month-olds to the distress of their peers. Child Dev (1981) 0.84
Single base mutation in the hormone binding domain of the thyroid hormone receptor beta gene in generalised thyroid hormone resistance demonstrated by single stranded conformation polymorphism analysis. Biochem Biophys Res Commun (1991) 0.83
Involvement of p16CDKN2A in cell cycle delays after low dose UV irradiation. Mutat Res (1998) 0.83
Lack of augmentation of tumor spectrum or severity in dual heterozygous Men1 and Rb1 knockout mice. Oncogene (2006) 0.83
Molecular tools for presymptomatic testing in multiple endocrine neoplasia type 1. J Intern Med (1995) 0.82
Loss of alleles on the short arm of chromosome 11 in a hepatoblastoma from a child with Beckwith-Wiedemann syndrome. Hum Genet (1988) 0.81
Origin of rare Ha-ras alleles: relationship of VTR length to a 5' polymorphic Xho I site. Genet Res (1989) 0.81
Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis. Br J Pharmacol (2013) 0.81
A cluster of cases of feline dysautonomia (Key-Gaskell syndrome) in a closed colony of cats. Vet Rec (1995) 0.80
Loss of heterozygosity studies in squamous cell carcinomas of the head and neck. Head Neck (1997) 0.80
Restoration of CDKN2A into melanoma cells induces morphologic changes and reduction in growth rate but not anchorage-independent growth reversal. J Invest Dermatol (1997) 0.80
Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int J Cancer (1994) 0.79
Mutation analysis of the CDKN2A promoter in Australian melanoma families. Genes Chromosomes Cancer (2001) 0.79
Contribution of germline MLH1 and MSH2 mutations to lobular carcinoma in situ of the breast. Cancer Lett (2001) 0.79
Ocular melanoma is not associated with CDKN2A or MC1R variants--a population-based study. Melanoma Res (2003) 0.79
Catering services. Measuring the wasteline. Health Serv J (1997) 0.78
Human cerberus related gene CER1 maps to chromosome 9. Genomics (1999) 0.78
Determining factors which predict response to primary medical therapy in breast cancer using a single fine needle aspirate with immunocytochemical staining and flow cytometry. Virchows Arch (1995) 0.78
Effect of N-hydroxyparacetamol on cell cycle progression. Biochem Pharmacol (1986) 0.78
Oncology: the role of the Macmillan nurse. Nurs Stand (1991) 0.78
Bicalutamide dosages used in the treatment of prostate cancer. Prostate (1999) 0.78
Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. J Clin Oncol (1992) 0.77
UV induction of transforming growth factor alpha in melanoma cell lines is a posttranslational event. J Cell Physiol (1992) 0.77
Injectable silicone implants as vaccine delivery vehicles. Vaccine (2002) 0.77
Refined localization of the melanoma (MLM) gene on chromosome 9p by analysis of allelic deletions. Oncogene (1994) 0.77
Cost effectiveness of statin therapy for the primary prevention of coronary heart disease. Ir Med J (2006) 0.76